{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:40:14Z","timestamp":1792215614385,"version":"4.4.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, tumor immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic effects. V-domain Ig suppressor of T-cell activation (VISTA) is a new type of immune checkpoint receptor that is highly expressed in various tumors. It is co-expressed with PD-1, T-cell immunoglobulin domain, mucin domain-3 (Tim-3), T-cell immunoglobulin, and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and is associated with prognosis, which suggests that it may be a target for immunotherapy. As an immune checkpoint receptor with no mature drugs, VISTA is highly expressed in acute myeloid leukemia (AML), multiple myeloma (MM), and other hematological malignancies; however, its pathogenic mechanism should be defined to better guide treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1466839","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T06:24:28Z","timestamp":1734416668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["VISTA in hematological malignancies: a review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuanjia","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264327","article-title":"Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors","volume":"14","author":"Roy","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12525","article-title":"Immunoregulatory functions of VISTA","volume":"276","author":"Nowak","year":"2017","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0563-2","article-title":"Acidity changes immunology: a new VISTA pathway","volume":"21","author":"Mahoney","year":"2020","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.148","article-title":"The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation","volume":"15","author":"Xu","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116100","article-title":"Expression and function of VISTA on myeloid cells","volume":"222","author":"Li","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100660","article-title":"Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models","volume":"187","author":"Flies","year":"2011","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","article-title":"VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.625808","article-title":"Structural basis of VSIG3: the ligand for VISTA","volume":"12","author":"Xie","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e005714","DOI":"10.1136\/jitc-2022-005714","article-title":"T lymphocytes induce human cancer cells derived from solid Malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins","volume":"11","author":"Schlichtner","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi7418","article-title":"LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses","volume":"9","author":"Ta","year":"2024","journal-title":"Sci Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608609","article-title":"The promising igSF11 immune checkpoint is highly expressed in advanced human gliomas and associates to poor prognosis","volume":"10","author":"Ghouzlani","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.8.3010.bloodjournal8883010","article-title":"P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells","volume":"88","author":"Laszik","year":"1996","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.immuni.2016.05.011","article-title":"PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion","volume":"44","author":"Tinoco","year":"2016","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.9.6078","article-title":"Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin","volume":"272","author":"Wada","year":"1997","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1332205","article-title":"Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/med.20249","article-title":"Therapeutic potential of Galectin-9 in human disease","author":"Wiersma","year":"2013","journal-title":"Med Res Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1131379","article-title":"Galectin-9 promotes natural killer cells activity via interaction with CD44","volume":"14","author":"Rahmati","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081066","article-title":"Influence of galectin-9 treatment on the phenotype and function of NK-92MI cells in the presence of different serum supplements","volume":"11","author":"Meggyes","year":"2021","journal-title":"Biomolecules"},{"key":"B29","article-title":"Treating cancer by blocking the interaction of vista and its binding partner","author":"Sun","year":"2019"},{"key":"B30","article-title":"Identification of VSIG8 as the putative vista receptor and its use thereof to produce VISTA\/VSIG8 modulators","author":"Molloy","year":"2017"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01244-4","article-title":"A small molecule inhibitor of VSIG-8 prevents its binding to VISTA","volume":"40","author":"Chen","year":"2022","journal-title":"Invest New Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1038\/s41467-023-39769-8","article-title":"The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease","volume":"14","author":"Fu","year":"2023","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133263","article-title":"Regulation and function of matrix metalloproteinase-13 in cancer progression and metastasis","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax1159","article-title":"PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus","volume":"11","author":"Han","year":"2019","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13075-017-1474-y","article-title":"VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes","volume":"19","author":"Ceeraz","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumor cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02641","article-title":"Defining the signature of VISTA on myeloid cell chemokine responsiveness","volume":"10","author":"Broughton","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.08.008","article-title":"Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy","volume":"86","author":"Im","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid Malignant pleural mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2542","article-title":"Spatially resolved and quantitative analysis of VISTA\/PD-1H as a novel immunotherapy target in human non-small cell lung cancer","volume":"24","author":"Villarroel-Espindola","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0642-z","article-title":"Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy","volume":"10","author":"Hong","year":"2019","journal-title":"Protein Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2227-8","article-title":"Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors","volume":"67","author":"Xie","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0507","article-title":"Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment","volume":"7","author":"Deng","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40164-024-00516-4","article-title":"Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation","volume":"13","author":"Notarantonio","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1469594","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical significance of macrophage heterogeneity in human Malignant tumors","volume":"105","author":"Komohara","year":"2014","journal-title":"Cancer Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.69","article-title":"M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4\/IL-10 signaling pathway","volume":"93","author":"Liu","year":"2013","journal-title":"Lab Invest"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.10.4926","article-title":"TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice","volume":"155","author":"Maeda","year":"1995","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40164-024-00501-x","article-title":"VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses","volume":"13","author":"Lin","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cytogfr.2018.01.007","article-title":"The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer","volume":"39","author":"Farajzadeh Valilou","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","article-title":"VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance","volume":"11","author":"Schaafsma","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101151","article-title":"CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells","volume":"4","author":"Zhang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0117","article-title":"Effective antitumor immunity can be triggered by targeting VISTA in combination with a TLR3-specific adjuvant","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314885","article-title":"Comprehensive transcriptomic analysis of VISTA in acute myeloid leukemia: insights into its prognostic value","volume":"23","author":"Pagliuca","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int J Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e164325","DOI":"10.1172\/JCI164325","article-title":"PD-1H\/VISTA mediates immune evasion in acute myeloid leukemia","volume":"134","author":"Kim","year":"2024","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1968-0","article-title":"Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma","volume":"66","author":"Wu","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-023-01410-y","article-title":"Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia","volume":"16","author":"Mo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113661","article-title":"VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073587","article-title":"Immunological prognostic factors in multiple myeloma","volume":"22","author":"B\u0119bnowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1014904","article-title":"Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092219","article-title":"V-domain ig suppressor of T cell activation (VISTA) expression is an independent prognostic factor in multiple myeloma","volume":"13","author":"Mutsaers","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e00181","DOI":"10.1097\/BS9.0000000000000181","article-title":"Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets","volume":"6","author":"Wang","year":"2024","journal-title":"Blood Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/jclinpath-2019-206117","article-title":"Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas","volume":"73","author":"Murga-Zamalloa","year":"2020","journal-title":"J Clin Pathol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-657379","article-title":"Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1907059","article-title":"VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer\/T-cell lymphoma","volume":"10","author":"He","year":"2021","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2018.1440400","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumor immunotherapy","volume":"27","author":"Li","year":"2019","journal-title":"J Drug Targeting"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e14504","article-title":"SNS-101, a highly selective monoclonal antibody against the active form of VISTA, demonstrates significantly reduced cytokine release","volume":"40","author":"van der Horst","year":"2022","journal-title":"JCO"},{"key":"B73","doi-asserted-by":"publisher","first-page":"TPS2664","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2664","article-title":"A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors","volume":"41","author":"Ahnert","year":"2023","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0761","article-title":"Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 antiVISTA antibody in patients with advanced solid tumors","volume":"10","author":"Noelle","year":"2022","journal-title":"Soc Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1466839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T06:24:32Z","timestamp":1734416672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1466839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2024.1466839"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1466839","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"article-number":"1466839"}}